UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $88.47 Million Stake in Revvity, Inc. (NYSE:RVTY)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Revvity, Inc. (NYSE:RVTY - Free Report) by 15.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 792,683 shares of the company's stock after buying an additional 108,605 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.65% of Revvity worth $88,471,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in RVTY. HB Wealth Management LLC grew its position in Revvity by 4.6% in the fourth quarter. HB Wealth Management LLC now owns 2,380 shares of the company's stock valued at $266,000 after acquiring an additional 104 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in shares of Revvity by 55.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock worth $43,000 after purchasing an additional 138 shares in the last quarter. Atomi Financial Group Inc. lifted its holdings in Revvity by 8.8% during the 4th quarter. Atomi Financial Group Inc. now owns 1,861 shares of the company's stock valued at $208,000 after purchasing an additional 151 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in Revvity by 87.0% in the fourth quarter. Janney Montgomery Scott LLC now owns 7,891 shares of the company's stock valued at $881,000 after buying an additional 3,672 shares in the last quarter. Finally, Fifth Third Bancorp boosted its position in Revvity by 9.6% in the fourth quarter. Fifth Third Bancorp now owns 5,362 shares of the company's stock valued at $598,000 after buying an additional 469 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Stock Up 0.5%

Shares of RVTY traded up $0.48 during midday trading on Thursday, hitting $91.82. The stock had a trading volume of 1,101,872 shares, compared to its average volume of 954,248. The firm has a market cap of $10.82 billion, a price-to-earnings ratio of 41.55, a price-to-earnings-growth ratio of 3.82 and a beta of 1.02. The company has a 50 day simple moving average of $95.69 and a two-hundred day simple moving average of $108.64. Revvity, Inc. has a twelve month low of $88.01 and a twelve month high of $129.50. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.96 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The firm had revenue of $664.76 million during the quarter, compared to the consensus estimate of $662.30 million. During the same quarter in the prior year, the firm posted $0.98 EPS. The business's revenue was up 2.3% on a year-over-year basis. On average, analysts anticipate that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, July 18th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.30%. Revvity's dividend payout ratio is 11.91%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on RVTY. Raymond James reissued an "outperform" rating and issued a $120.00 target price (down from $145.00) on shares of Revvity in a report on Tuesday, April 29th. Barclays decreased their target price on Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. UBS Group raised Revvity from a "neutral" rating to a "buy" rating and cut their price target for the company from $145.00 to $115.00 in a report on Thursday, May 1st. Wells Fargo & Company decreased their price objective on shares of Revvity from $130.00 to $102.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Revvity from $120.00 to $100.00 and set a "neutral" rating for the company in a research report on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $125.64.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.